BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38468814)

  • 21. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
    Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
    Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
    Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
    EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CircAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity.
    Xu Y; Jiang T; Wu C; Zhang Y
    Biotechnol Lett; 2020 Jul; 42(7):1123-1135. PubMed ID: 32170433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
    Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
    Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
    Xu P; Wang H; Pan H; Chen J; Deng C
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DICER activates autophagy and promotes cisplatin resistance in non-small cell lung cancer by binding with let-7i-5p.
    Li C; Chen L; Song W; Peng B; Zhu J; Fang L
    Acta Histochem; 2021 Oct; 123(7):151788. PubMed ID: 34543777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
    Chen C; Zhang M; Zhang Y
    Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
    Lu T; Lu W; Jia C; Lou S; Zhang Y
    Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
    Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
    Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating
    Wang X; Wang H; Jiang H; Qiao L; Guo C
    Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285
    [No Abstract]   [Full Text] [Related]  

  • 38. circANKRD28 inhibits cisplatin resistance in non-small-cell lung cancer through the miR-221-3p/SOCS3 axis.
    Song S; Shi Y; Zeng D; Xu J; Yang Y; Guo W; Zheng Y; Tang H
    J Gene Med; 2023 Apr; 25(4):e3478. PubMed ID: 36740786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism of METTL14-mediated m
    Gong S; Wang S; Shao M
    J Mol Med (Berl); 2022 Dec; 100(12):1771-1785. PubMed ID: 36352154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
    Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X
    Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.